NOX 14.3% 8.0¢ noxopharm limited

Novartis Vision trial result, page-11

  1. 1,610 Posts.
    lightbulb Created with Sketch. 409
    Thanks, though Graham seems to agree with my proposition:

    "The VISION study compared Lu-PSMA-617 with standard of care in men with metastatic castrate-resistant prostate cancer (mCRPC) who had received at least two previous lines of therapy ...This compares with the LuPIN trial that tested the combination of Lu-PSMA-617 and Veyonda in men with end-stage mCRPC who had progressed on at least three previous lines of therapy."

    (from today's announcement; my emphasis)
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
(20min delay)
Last
8.0¢
Change
0.010(14.3%)
Mkt cap ! $23.37M
Open High Low Value Volume
7.0¢ 8.0¢ 7.0¢ $4.207K 56.02K

Buyers (Bids)

No. Vol. Price($)
1 118527 7.5¢
 

Sellers (Offers)

Price($) Vol. No.
8.0¢ 4999 1
View Market Depth
Last trade - 16.10pm 21/06/2024 (20 minute delay) ?
NOX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.